1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > 2011 Radiotherapy Today and Tomorrow

2011 Radiotherapy Today and Tomorrow

  • December 2011
  • -
  • Frost & Sullivan

This study looks at emerging trends in the radiosurgery market and the residual impact of the financial crisis from both a market and an end-user hospital perspective. Stereotactic Radiosurgery (SRS) is an advanced form of radiotherapy capable of synchronizing tumor detection, surgical guidance, and radiation delivery components in a manner that can treat localized tumors. SRS systems, due to their accuracy and precision, minimize damage to healthy tissue, making them ideal for treatment of complicated tumors located near the brain or spine. This survey is intended to gather qualitative feedback on how radiosurgery centers plan to work around external challenges.

Table Of Contents

2011 Radiotherapy Today and Tomorrow
Table of Contents

Market Overview and Metrics 4
Case Study: Gamma Knife Surgery Program Perceptions 24
About Frost and Sullivan 45


View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • April 2015
  • by Global Data

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023 Summary Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all ...

Non-Small Cell Lung Cancer: KOL Insight

Non-Small Cell Lung Cancer: KOL Insight

  • $ 7 495
  • Industry report
  • July 2015
  • by Firstword Pharma

Non-Small Cell Lung Cancer: KOL Insight offers detailed expert opinion on the continuing evolution of the treatment paradigm for EGFR/ALK positive and negative NSCLC, and the potential for targeting ...

Breast Cancer: KOL Insight

Breast Cancer: KOL Insight

  • $ 7 495
  • Industry report
  • May 2015
  • by Firstword Pharma

How will breast cancer be treated in the years ahead – and what targeted therapies represent the greatest potential in terms of transforming disease therapy? KOL Insight: Breast Cancer provides a comprehensive ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.